
## Jake R Morgan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3142069/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Potential barriers to filling buprenorphine and naltrexone prescriptions among a retrospective cohort of individuals with opioid use disorder. Journal of Substance Abuse Treatment, 2022, 133, 108540.	2.8	8
2	Broadening access to naloxone: Community predictors of standing order naloxone distribution in Massachusetts. Drug and Alcohol Dependence, 2022, 230, 109190.	3.2	8
3	Communityâ€based naloxone coverage equity for the prevention of opioid overdose fatalities in racial/ethnic minority communities in Massachusetts and Rhode Island. Addiction, 2022, 117, 1372-1381.	3.3	8
4	Variation in Initiation, Engagement, and Retention on Medications for Opioid Use Disorder Based on Health Insurance Plan Design. Medical Care, 2022, 60, 256-263.	2.4	15
5	Determining the lower limit of detection required for HCV viral load assay for test of cure following directâ€acting antiviralâ€based treatment regimens: Evidence from a global data set. Journal of Viral Hepatitis, 2022, 29, 474-486.	2.0	3
6	Populationâ€level impact of initiating pharmacotherapy and linking to care people with opioid use disorder at inpatient medically managed withdrawal programs: an effectiveness and costâ€effectiveness analysis. Addiction, 2022, 117, 2450-2461.	3.3	3
7	The Determining Effective Testing in Emergency Departments and Care Coordination on Treatment Outcomes (DETECT) for Hepatitis C (Hep C) Screening Trial: rationale and design of a multi-center pragmatic randomized clinical trial of hepatitis C screening in emergency departments. Trials, 2022, 23, 354	1.6	3
8	Impact of prenatal substance use policies on commercially insured pregnant females with opioid use disorder. Journal of Substance Abuse Treatment, 2022, 140, 108800.	2.8	7
9	Commentary on Karnik <i>et al</i> .: Harmonization now—the need for consistent, validated measures to identify opioid use disorder in observational data. Addiction, 2022, 117, 2448-2449.	3.3	3
10	Prevalence of HIV Preexposure Prophylaxis Prescribing Among Persons With Commercial Insurance and Likely Injection Drug Use. JAMA Network Open, 2022, 5, e2221346.	5.9	10
11	Outcomes Associated With Medications for Opioid Use Disorder Among Persons Hospitalized for Infective Endocarditis. Clinical Infectious Diseases, 2021, 72, 472-478.	5.8	42
12	HCV Viral Load Greater Than 1000ÂIU/ml at Time of Virologic Failure in Direct-Acting Antiviral-Treated Patients. Advances in Therapy, 2021, 38, 1690-1700.	2.9	2
13	Projected Estimates of Opioid Mortality After Community-Level Interventions. JAMA Network Open, 2021, 4, e2037259.	5.9	37
14	Opioid use disorder and overdose among youth following an initial opioid prescription. Addiction, 2021, 116, 2790-2800.	3.3	9
15	Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort. Drug and Alcohol Dependence, 2021, 225, 108764.	3.2	25
16	Eligibility for cervical cancer screening exit: Comparison of a national and safety net cohort. Gynecologic Oncology, 2021, 162, 308-314.	1.4	11
17	Targeting community-based naloxone distribution using opioid overdose death rates: A descriptive analysis of naloxone rescue kits and opioid overdose deaths in Massachusetts and Rhode Island. International Journal of Drug Policy, 2021, 98, 103435.	3.3	13
18	Cost-effectiveness of Hepatitis C Virus Treatment Models for People Who Inject Drugs in Opioid Agonist Treatment Programs. Clinical Infectious Diseases, 2020, 70, 1397-1405.	5.8	13

JAKE R MORGAN

#	Article	IF	CITATIONS
19	Patient Outcomes Following Total Joint Replacement Surgery: AÂComparison of Hospitals and Ambulatory Surgery Centers. Journal of Arthroplasty, 2020, 35, 7-11.	3.1	55
20	Opioid overdose and inpatient care for substance use disorder care in Massachusetts. Journal of Substance Abuse Treatment, 2020, 112, 42-48.	2.8	13
21	Health economic design for cost, cost-effectiveness and simulation analyses in the HEALing Communities Study. Drug and Alcohol Dependence, 2020, 217, 108336.	3.2	8
22	Comparison of Rates of Overdose and Hospitalization After Initiation of Medication for Opioid Use Disorder in the Inpatient vs Outpatient Setting. JAMA Network Open, 2020, 3, e2029676.	5.9	17
23	Payments for outpatient joint replacement surgery: A comparison of hospital outpatient departments and ambulatory surgery centers. Health Services Research, 2020, 55, 218-223.	2.0	11
24	Inappropriate Antibiotic Prescribing for Acute Bronchitis in Children and Impact on Subsequent Episodes of Care and Treatment. Pediatric Infectious Disease Journal, 2019, 38, 271-274.	2.0	8
25	Cost-effectiveness of integrating buprenorphine-naloxone treatment for opioid use disorder into clinical care for persons with HIV/hepatitis C co-infection who inject opioids. International Journal of Drug Policy, 2019, 72, 160-168.	3.3	23
26	Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort. Drug and Alcohol Dependence, 2019, 200, 34-39.	3.2	113
27	Will converting naloxone to overâ€ŧheâ€counter status increase pharmacy sales?. Health Services Research, 2019, 54, 764-772.	2.0	25
28	Disproportionate Exposure to Antibiotics in Children at Risk for Invasive Pneumococcal Disease: Potential for Emerging Resistance and Opportunity for Antibiotic Stewardship. Journal of the Pediatric Infectious Diseases Society, 2019, 8, 63-65.	1.3	5
29	Cost-effectiveness of hepatitis C screening and treatment linkage intervention in US methadone maintenance treatment programs. Drug and Alcohol Dependence, 2018, 185, 411-420.	3.2	22
30	The Effect of Shorter Treatment Regimens for Hepatitis C on Population Health and Under Fixed Budgets. Open Forum Infectious Diseases, 2018, 5, ofx267.	0.9	7
31	Obstetric Outcomes After Failed Hysteroscopic and Laparoscopic Sterilization Procedures. Obstetrics and Gynecology, 2018, 131, 253-261.	2.4	2
32	Implementation of a Nationwide Health Economic Consultation Service to Assist Substance use Researchers: Lessons Learned. Substance Abuse, 2018, 39, 185-189.	2.3	4
33	Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population. Journal of Substance Abuse Treatment, 2018, 85, 90-96.	2.8	233
34	A Qualitative Study of the Real-world Experiences of Infectious Diseases Fellows Regarding Antibiotic Stewardship. Open Forum Infectious Diseases, 2018, 5, ofy102.	0.9	8
35	Estimated Prevalence of Opioid Use Disorder in Massachusetts, 2011–2015: A Capture–Recapture Analysis. American Journal of Public Health, 2018, 108, 1675-1681.	2.7	109
36	Economic evaluation of HCV testing approaches in low and middle income countries. BMC Infectious Diseases, 2017, 17, 697.	2.9	43

JAKE R MORGAN

#	Article	IF	CITATIONS
37	Cost Effectiveness and Cost Containment in the Era of Interferon-Free Therapies to Treat Hepatitis C Virus Genotype 1. Open Forum Infectious Diseases, 2017, 4, ofw266.	0.9	14
38	Gynecologic Outcomes After Hysteroscopic and Laparoscopic Sterilization Procedures. Obstetrical and Gynecological Survey, 2017, 72, 82-83.	0.4	0
39	Homelessness, HIV, and Incomplete Viral Suppression. Journal of Health Care for the Poor and Underserved, 2016, 27, 145-156.	0.8	35
40	Getting What You Pay For. Sexually Transmitted Diseases, 2016, 43, 18-22.	1.7	2
41	Gynecologic Outcomes After Hysteroscopic and Laparoscopic Sterilization Procedures. Obstetrics and Gynecology, 2016, 128, 843-852.	2.4	20
42	Using Medical Claims for Policy Effectiveness Surveillance: Reimbursement and Utilization of Abdomen/Pelvis Computed Tomography Scans. Health Services Research, 2015, 50, 1910-1926.	2.0	12
43	Predictors of Frequent Emergency Room Visits among a Homeless Population. PLoS ONE, 2015, 10, e0124552.	2.5	39
44	Antibiotics for Respiratory Tract Infections: A Comparison of Prescribing in an Outpatient Setting. Infection Control and Hospital Epidemiology, 2015, 36, 153-159.	1.8	36
45	Evaluating Quality of Care for Sexually Transmitted Infections in Different Clinical Settings. Sexually Transmitted Diseases, 2015, 42, 717-724.	1.7	7
46	Capsule Commentary on Tannenbaum et al., Nudging Physician Prescription Decisions by Partitioning the Order Set: Results of a Vignette-Based Study. Journal of General Internal Medicine, 2015, 30, 343-343.	2.6	2
47	The Cost-Effectiveness of Sofosbuvir-Based Regimens for Treatment of Hepatitis C Virus Genotype 2 or 3 Infection. Annals of Internal Medicine, 2015, 162, 619-629.	3.9	92
48	Coal power plant emission exposure and its effect on education access. Zeitschrift Fur Gesundheitswissenschaften, 2014, 22, 313-321.	1.6	1
49	Characteristics of patients who accept and decline ED rapid HIV testing. American Journal of Emergency Medicine, 2014, 32, 1109-1112.	1.6	15